Equities

Mendus AB (publ)

Mendus AB (publ)

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)8.19
  • Today's Change0.11 / 1.36%
  • Shares traded20.11k
  • 1 Year change-5.90%
  • Beta1.2686
Data delayed at least 15 minutes, as of Sep 20 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy1
Outperform0
Hold0
Sell0
Strong Sell0

Share price forecast in SEK

The 2 analysts offering 12 month price targets for Mendus AB (publ) have a median target of 25.00, with a high estimate of 36.00 and a low estimate of 14.00. The median estimate represents a 205.36% increase from the last price of 8.19.
High339.7%36.00
Med205.4%25.00
Low71.0%14.00

Earnings history & estimates in SEK

On Aug 23, 2024, Mendus AB (publ) reported 2nd quarter 2024 losses of -0.76 per share.
The next earnings announcement is expected on Nov 08, 2024.
Average growth rate+5.00%
Mendus AB (publ) reported annual 2023 losses of -4.40 per share on Feb 14, 2024.
Average growth rate+32.40%
More ▼

Revenue history & estimates in SEK

Immunicum AB (publ) had revenues for the full year 2023 of 29.61m. This was 777.42% above the prior year's results.
Average growth rate+259.14%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.